Latest Aurinia Pharmaceuticals Inc. (IPHAF) Headlines
Concise Analysis on the International Head Mounted Display Market - Forecast to 2019
M2 - Wed Feb 05, 4:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/8qnn9s/head_mounted) has announced the addition of the "Concise Analysis on the International Head Mounted Display Market - Forecast to 2019" report to their offering. Head mounted displays are head worn display devices that include small display optics in front of either one (monocular head mounted displays) or each eye (binocular head mounted displays). The display optic projects a virtual environment in front of wearer's eye. In general, HMDs can be segmented into two broad categories namely see-through' HMDs and look-at' HMDs. The look-at' HMDs allow wearers to see only the CGI (Computer Generated Image) projected by HMDs. On the contrary, see-through' HMDs allow superimposing of a CGI (Computer Generated Image) upon a real world view. The growing popularity for compact, portable and wearable computing devices has lead to the resurgence of head mounted displays in recent years. Increased penetration of HMDs in the consumer market coupled with declining prices of components such as microdisplays is expected to fuel market growth over the next few years. Microdisplays are one of the key embedded components in every NTE (Near-To-Eye) devices that are coupled with an optic system for providing enlarged, high quality image in front of wearer's eye. Use of HMDs for automotive prototyping in terms of virtually designing a vehicle or a car and evaluating the position of different parts provides a sound opportunity for the growth of HMD market. Key Topics Covered: 1 Preface 2 Executive Summary 3 Head Mounted Display Market Analysis 4 Head Mounted Display Market, by End-use 5 Head Mounted Display Market, by Product 6 Head Mounted Display Market, by Components 7 Head Mounted Display Market, by Applications 8 Head Mounted Display Market, by Geography 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - BAE Systems Plc - Elbit Systems Ltd - eMagin Corporation - Forth Dimension Displays - Kopin Corporation - NEC Corporation - Rockwell Collins, Inc - Seiko Epson Corporation - Sensics, Inc - Sony Corporation - Thales Group - Universal Display Corporation - Vuzix Corporation For more information visit http://www.researchandmarkets.com/research/8qnn9s/head_mounted
ILJIN Life Science Co., Ltd. - Acquisition of additional securities of Aurinia Pharmaceuticals Inc.
CNW Group - Wed Nov 13, 10:41AM CST
ILJIN Life Science Co., Ltd. ("ILJIN Life Science") announces pursuant to National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues that it has acquired, along with ILJIN Semiconductor Co., Ltd. ("ILJIN Seminconductor" and together with ILJIN Life Science, "ILJIN"), a related party and joint actor of ILJIN Life Science, ownership and control, through a series of private placements and completion of a plan of arrangement (the "Arrangement") between Isotechnika Pharma Inc. ("Isotechnika") and Aurinia Pharmaceuticals Inc. ("Old Aurinia"), of an aggregate of 164,001,360 additional Common shares (the "Additional Shares") and 21,111,111 Common share purchase warrants (the "Warrants" and together with the Additional Shares, the "Additional Securities") in the capital of Aurinia Pharmaceuticals Inc. (formerly Isotechnika) ("Aurinia").
Innovotech Announces New Director and Grant of Stock Options
Marketwire - Thu Oct 31, 5:01AM CDT
Innovotech Inc. (TSX VENTURE: IOT) ("Innovotech") is pleased to announce the appointment of Robert Huizinga to its board of directors. Mr. Huizinga is currently Vice President, Clinical Affairs of Aurinia Pharmaceuticals Inc., formerly Isotechnika Pharma Inc. Prior to this, Mr. Huizinga was at the University of Alberta Hospitals in the Division of Nephrology & Immunology as a Nephrology Nurse Clinician and Research Epidemiologist. He holds a Master's Degree in Medical Sciences - Epidemiology, is a Registered Nurse and has published many articles with respect to his areas of expertise.
Aurinia Announces Official Name, Trading Symbol Change and Implementation of Share Consolidation
GlobeNewswire - Tue Oct 22, 3:45PM CDT
Isotechnika Pharma Inc. (TSX-V:ISA) (the "Company") announced that, further to its press release of September 30, 2013, it has officially changed its name to Aurinia Pharmaceuticals Inc. ("Aurnia") and that its common shares (the "Shares") will be posted for trading on a 50:1 consolidated basis (the "Consolidation") on the TSX Venture Exchange at the opening of market on October 23, 2013 under the new trading symbol "AUP".
Aurinia Pharmaceuticals Announces Post-Merger Leadership Changes and Strategic Restructuring
GlobeNewswire - Tue Oct 22, 6:45AM CDT
Isotechnika Pharma Inc., now operating as Aurinia Pharmaceuticals Inc. (TSX-V:ISA) ("Aurinia" or the "Company"), announced today a strategic restructuring, including senior management changes and staff reductions, designed to further position the newly merged company to successfully bring voclosporin to market as a therapy for lupus nephritis.
Kidney Transplantation - Pipeline Review, H2 2013
M2 - Mon Oct 14, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nn8sz9/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2013" report to their offering. 'Kidney Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Transplantation. Scope - A snapshot of the global therapeutic scenario for Kidney Transplantation. - A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Kyowa Hakko Kirin Co., Ltd. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Pharming Group N.V. Isotechnika Pharma Inc. Astellas Pharma Inc. ViroPharma Incorporated 4SC AG LifeCycle Pharma A/S NPS Pharmaceuticals, Inc. La Jolla Pharmaceutical Company Alexion Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. Hansa Medical AB Digna Biotech, S.L. Viron Therapeutics, Inc. Opsona Therapeutics Ltd. Angion Biomedica Corp. NovImmune SA Tolera Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/nn8sz9/kidney About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uveitis - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cbbpd2/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2013" report to their offering. 'Uveitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis. Scope - A snapshot of the global therapeutic scenario for Uveitis. - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uveitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Uveitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. pSivida Corp. Inovio Biomedical Corporation Santen Pharmaceutical Co., Ltd. Apitope International NV Novartis AG Isotechnika Pharma Inc. TheraKine Inc. Enzo Biochem, Inc. Can-Fite BioPharma Ltd. Regeneron Pharmaceuticals, Inc. XOMA Ltd. Hanall Pharmaceutical Co., Ltd. Artielle ImmunoTherapeutics, Inc. ProtAffin Biotechnologie AG Endocyte, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/cbbpd2/uveitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg6q26/amyotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Multiple Sclerosis - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cwcj2q/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2013" report to their offering. 'Multiple Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. Scope - A snapshot of the global therapeutic scenario for Multiple Sclerosis. - A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. Baxter International Inc. F. Hoffmann-La Roche Ltd. Biogen Idec Inc. Amgen Inc. Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc MedImmune LLC Daiichi Sankyo Company, Ltd Cytokine PharmaSciences, Inc. Plexxikon Inc. XenoPort, Inc. Apitope International NV Novartis AG Isotechnika Pharma Inc. Aphios Corporation Acorda Therapeutics, Inc. Actelion Ltd Dong-A Pharmaceutical Co., Ltd. Elan Corporation, plc Kissei Pharmaceutical Co., Ltd. and many more... For more information visit http://www.researchandmarkets.com/research/cwcj2q/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Psoriasis - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gxpkrs/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2013" report to their offering. 'Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. Scope - A snapshot of the global therapeutic scenario for Psoriasis. - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Boehringer Ingelheim GmbH Valeant Pharmaceuticals International Amgen Inc. Antares Pharma, Inc. GlaxoSmithKline plc Echo Therapeutics, Inc. Stiefel Laboratories, Inc. XenoPort, Inc. ApoPharma Piramal Healthcare Limited Celltrion, Inc. Isotechnika Pharma Inc. Dr. Reddy's Laboratories Limited LEO Pharma A/S Ono Pharmaceutical Co., Ltd. Pfizer Inc. Teva Pharmaceutical Industries Limited UCB Group Cell Therapeutics, Inc. and many more..... For more information visit http://www.researchandmarkets.com/research/gxpkrs/psoriasis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Alzheimer's Disease Report - Pipeline Review
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d9h2c7/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2013" report to their offering. 'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. Scope - A snapshot of the global therapeutic scenario for Alzheimer's Disease. - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Alzheimer's Disease Therapeutics Development - Click the link below to view the full list of companies - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - United Biomedical, Inc. - Taisho Pharmaceutical Co., Ltd. - Euroscreen S.A. - Applied NeuroSolutions, Inc. - Avineuro Pharmaceuticals, Inc. - Panacea Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - Novartis AG - Isotechnika Pharma Inc. - Samyang Corporation - Aphios Corporation - Alzhyme Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - H Lundbeck A/S - Jeil Pharmaceutical Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier For more information visit http://www.researchandmarkets.com/research/d9h2c7/alzheimers
Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2563g/transplantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Isotechnika Shareholders Approve Merger With Aurinia at Annual and Special Meeting
GlobeNewswire - Fri Aug 16, 7:30AM CDT
Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced that at its Annual and Special Meeting of Shareholders held on August 15, 2013 in Vancouver, British Columbia (the "Meeting"), shareholders approved the issuance of Isotechnika shares to be issued in connection with the proposed plan of arrangement (the "Arrangement") pursuant to which, among other things, the Company will merge with privately-held Aurinia Pharmaceuticals Inc. (the "Merger Transaction").
Isotechnika Reports Second Quarter 2013 Financial Results
GlobeNewswire - Tue Aug 13, 5:46PM CDT
Isotechnika Pharma Inc. (TSX:ISA) (the "Company") has released its financial results for the second quarter ended June 30, 2013.
Isotechnika to Hold Annual and Special Meeting of Shareholders on August 15
GlobeNewswire - Thu Jul 25, 7:30AM CDT
Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") and privately-held Aurinia Pharmaceuticals Inc. ("Aurinia") issued a further update today with respect to the proposed merger of the two companies.
Isotechnika Provides Further Merger and Financings Update
GlobeNewswire - Thu Jun 27, 7:00AM CDT
Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") and privately-held Aurinia Pharmaceuticals Inc. ("Aurinia") issued a further update today with respect to the proposed merger of the two companies designed to create a premier clinical stage pharmaceutical company focused on the global nephrology market.
Isotechnika Pharma Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent
GlobeNewswire - Tue Jun 18, 6:45AM CDT
Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") today announced that it has received additional funding from the National Research Council Industrial Research Assistance Program ("NRC-IRAP") for its Non-Immunosuppressive Cyclophilin Antagonist Molecules ("NICAMs") program.
Isotechnika Reports First Quarter 2013 Financial Results
GlobeNewswire - Wed May 15, 4:00PM CDT
Isotechnika Pharma Inc. (TSX:ISA) (the "Company") has released its financial results for the first quarter ended March 31, 2013.
Concise Analysis on the International Head Mounted Display Market - Forecast to 2019
M2 - Wed Feb 05, 4:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/8qnn9s/head_mounted) has announced the addition of the "Concise Analysis on the International Head Mounted Display Market - Forecast to 2019" report to their offering. Head mounted displays are head worn display devices that include small display optics in front of either one (monocular head mounted displays) or each eye (binocular head mounted displays). The display optic projects a virtual environment in front of wearer's eye. In general, HMDs can be segmented into two broad categories namely see-through' HMDs and look-at' HMDs. The look-at' HMDs allow wearers to see only the CGI (Computer Generated Image) projected by HMDs. On the contrary, see-through' HMDs allow superimposing of a CGI (Computer Generated Image) upon a real world view. The growing popularity for compact, portable and wearable computing devices has lead to the resurgence of head mounted displays in recent years. Increased penetration of HMDs in the consumer market coupled with declining prices of components such as microdisplays is expected to fuel market growth over the next few years. Microdisplays are one of the key embedded components in every NTE (Near-To-Eye) devices that are coupled with an optic system for providing enlarged, high quality image in front of wearer's eye. Use of HMDs for automotive prototyping in terms of virtually designing a vehicle or a car and evaluating the position of different parts provides a sound opportunity for the growth of HMD market. Key Topics Covered: 1 Preface 2 Executive Summary 3 Head Mounted Display Market Analysis 4 Head Mounted Display Market, by End-use 5 Head Mounted Display Market, by Product 6 Head Mounted Display Market, by Components 7 Head Mounted Display Market, by Applications 8 Head Mounted Display Market, by Geography 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - BAE Systems Plc - Elbit Systems Ltd - eMagin Corporation - Forth Dimension Displays - Kopin Corporation - NEC Corporation - Rockwell Collins, Inc - Seiko Epson Corporation - Sensics, Inc - Sony Corporation - Thales Group - Universal Display Corporation - Vuzix Corporation For more information visit http://www.researchandmarkets.com/research/8qnn9s/head_mounted
ILJIN Life Science Co., Ltd. - Acquisition of additional securities of Aurinia Pharmaceuticals Inc.
CNW Group - Wed Nov 13, 10:41AM CST
ILJIN Life Science Co., Ltd. ("ILJIN Life Science") announces pursuant to National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues that it has acquired, along with ILJIN Semiconductor Co., Ltd. ("ILJIN Seminconductor" and together with ILJIN Life Science, "ILJIN"), a related party and joint actor of ILJIN Life Science, ownership and control, through a series of private placements and completion of a plan of arrangement (the "Arrangement") between Isotechnika Pharma Inc. ("Isotechnika") and Aurinia Pharmaceuticals Inc. ("Old Aurinia"), of an aggregate of 164,001,360 additional Common shares (the "Additional Shares") and 21,111,111 Common share purchase warrants (the "Warrants" and together with the Additional Shares, the "Additional Securities") in the capital of Aurinia Pharmaceuticals Inc. (formerly Isotechnika) ("Aurinia").
Innovotech Announces New Director and Grant of Stock Options
Marketwire - Thu Oct 31, 5:01AM CDT
Innovotech Inc. (TSX VENTURE: IOT) ("Innovotech") is pleased to announce the appointment of Robert Huizinga to its board of directors. Mr. Huizinga is currently Vice President, Clinical Affairs of Aurinia Pharmaceuticals Inc., formerly Isotechnika Pharma Inc. Prior to this, Mr. Huizinga was at the University of Alberta Hospitals in the Division of Nephrology & Immunology as a Nephrology Nurse Clinician and Research Epidemiologist. He holds a Master's Degree in Medical Sciences - Epidemiology, is a Registered Nurse and has published many articles with respect to his areas of expertise.
Aurinia Announces Official Name, Trading Symbol Change and Implementation of Share Consolidation
GlobeNewswire - Tue Oct 22, 3:45PM CDT
Isotechnika Pharma Inc. (TSX-V:ISA) (the "Company") announced that, further to its press release of September 30, 2013, it has officially changed its name to Aurinia Pharmaceuticals Inc. ("Aurnia") and that its common shares (the "Shares") will be posted for trading on a 50:1 consolidated basis (the "Consolidation") on the TSX Venture Exchange at the opening of market on October 23, 2013 under the new trading symbol "AUP".
Aurinia Pharmaceuticals Announces Post-Merger Leadership Changes and Strategic Restructuring
GlobeNewswire - Tue Oct 22, 6:45AM CDT
Isotechnika Pharma Inc., now operating as Aurinia Pharmaceuticals Inc. (TSX-V:ISA) ("Aurinia" or the "Company"), announced today a strategic restructuring, including senior management changes and staff reductions, designed to further position the newly merged company to successfully bring voclosporin to market as a therapy for lupus nephritis.
Kidney Transplantation - Pipeline Review, H2 2013
M2 - Mon Oct 14, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nn8sz9/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2013" report to their offering. 'Kidney Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Transplantation. Scope - A snapshot of the global therapeutic scenario for Kidney Transplantation. - A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Kyowa Hakko Kirin Co., Ltd. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Pharming Group N.V. Isotechnika Pharma Inc. Astellas Pharma Inc. ViroPharma Incorporated 4SC AG LifeCycle Pharma A/S NPS Pharmaceuticals, Inc. La Jolla Pharmaceutical Company Alexion Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. Hansa Medical AB Digna Biotech, S.L. Viron Therapeutics, Inc. Opsona Therapeutics Ltd. Angion Biomedica Corp. NovImmune SA Tolera Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/nn8sz9/kidney About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uveitis - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cbbpd2/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2013" report to their offering. 'Uveitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis. Scope - A snapshot of the global therapeutic scenario for Uveitis. - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uveitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Uveitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. pSivida Corp. Inovio Biomedical Corporation Santen Pharmaceutical Co., Ltd. Apitope International NV Novartis AG Isotechnika Pharma Inc. TheraKine Inc. Enzo Biochem, Inc. Can-Fite BioPharma Ltd. Regeneron Pharmaceuticals, Inc. XOMA Ltd. Hanall Pharmaceutical Co., Ltd. Artielle ImmunoTherapeutics, Inc. ProtAffin Biotechnologie AG Endocyte, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/cbbpd2/uveitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg6q26/amyotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Multiple Sclerosis - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cwcj2q/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2013" report to their offering. 'Multiple Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. Scope - A snapshot of the global therapeutic scenario for Multiple Sclerosis. - A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. Baxter International Inc. F. Hoffmann-La Roche Ltd. Biogen Idec Inc. Amgen Inc. Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc MedImmune LLC Daiichi Sankyo Company, Ltd Cytokine PharmaSciences, Inc. Plexxikon Inc. XenoPort, Inc. Apitope International NV Novartis AG Isotechnika Pharma Inc. Aphios Corporation Acorda Therapeutics, Inc. Actelion Ltd Dong-A Pharmaceutical Co., Ltd. Elan Corporation, plc Kissei Pharmaceutical Co., Ltd. and many more... For more information visit http://www.researchandmarkets.com/research/cwcj2q/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Psoriasis - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gxpkrs/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2013" report to their offering. 'Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. Scope - A snapshot of the global therapeutic scenario for Psoriasis. - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Boehringer Ingelheim GmbH Valeant Pharmaceuticals International Amgen Inc. Antares Pharma, Inc. GlaxoSmithKline plc Echo Therapeutics, Inc. Stiefel Laboratories, Inc. XenoPort, Inc. ApoPharma Piramal Healthcare Limited Celltrion, Inc. Isotechnika Pharma Inc. Dr. Reddy's Laboratories Limited LEO Pharma A/S Ono Pharmaceutical Co., Ltd. Pfizer Inc. Teva Pharmaceutical Industries Limited UCB Group Cell Therapeutics, Inc. and many more..... For more information visit http://www.researchandmarkets.com/research/gxpkrs/psoriasis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Alzheimer's Disease Report - Pipeline Review
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d9h2c7/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2013" report to their offering. 'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. Scope - A snapshot of the global therapeutic scenario for Alzheimer's Disease. - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Alzheimer's Disease Therapeutics Development - Click the link below to view the full list of companies - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - United Biomedical, Inc. - Taisho Pharmaceutical Co., Ltd. - Euroscreen S.A. - Applied NeuroSolutions, Inc. - Avineuro Pharmaceuticals, Inc. - Panacea Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - Novartis AG - Isotechnika Pharma Inc. - Samyang Corporation - Aphios Corporation - Alzhyme Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - H Lundbeck A/S - Jeil Pharmaceutical Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier For more information visit http://www.researchandmarkets.com/research/d9h2c7/alzheimers
Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2563g/transplantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Isotechnika Shareholders Approve Merger With Aurinia at Annual and Special Meeting
GlobeNewswire - Fri Aug 16, 7:30AM CDT
Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced that at its Annual and Special Meeting of Shareholders held on August 15, 2013 in Vancouver, British Columbia (the "Meeting"), shareholders approved the issuance of Isotechnika shares to be issued in connection with the proposed plan of arrangement (the "Arrangement") pursuant to which, among other things, the Company will merge with privately-held Aurinia Pharmaceuticals Inc. (the "Merger Transaction").
Isotechnika Reports Second Quarter 2013 Financial Results
GlobeNewswire - Tue Aug 13, 5:46PM CDT
Isotechnika Pharma Inc. (TSX:ISA) (the "Company") has released its financial results for the second quarter ended June 30, 2013.
Isotechnika to Hold Annual and Special Meeting of Shareholders on August 15
GlobeNewswire - Thu Jul 25, 7:30AM CDT
Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") and privately-held Aurinia Pharmaceuticals Inc. ("Aurinia") issued a further update today with respect to the proposed merger of the two companies.
Isotechnika Provides Further Merger and Financings Update
GlobeNewswire - Thu Jun 27, 7:00AM CDT
Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") and privately-held Aurinia Pharmaceuticals Inc. ("Aurinia") issued a further update today with respect to the proposed merger of the two companies designed to create a premier clinical stage pharmaceutical company focused on the global nephrology market.
Isotechnika Pharma Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent
GlobeNewswire - Tue Jun 18, 6:45AM CDT
Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") today announced that it has received additional funding from the National Research Council Industrial Research Assistance Program ("NRC-IRAP") for its Non-Immunosuppressive Cyclophilin Antagonist Molecules ("NICAMs") program.
Isotechnika Reports First Quarter 2013 Financial Results
GlobeNewswire - Wed May 15, 4:00PM CDT
Isotechnika Pharma Inc. (TSX:ISA) (the "Company") has released its financial results for the first quarter ended March 31, 2013.
